Millipore Sigma Vibrant Logo
Attention: We have moved. Merck Millipore products are no longer available for purchase on MerckMillipore.com.Learn More

196876 BAY 41-2272 - CAS 256376-24-6 - Calbiochem

A cell-permeable pyrazolopyridinylpyrimidine compound that acts as a selective and potent stimulator of soluble guanylate cyclase (effective dose ~ 0.1 nM to 100 µM using recombinant soluble guanylate cyclase).

BAY 41-2272 - CAS 256376-24-6 - Calbiochem MSDS (material safety data sheet) or SDS, CoA and CoQ, dossiers, brochures and other available documents.

Synonyms: 5-Cyclopropyl-2-[1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-4-ylamine

Primary Target: Soluble guanylate cyclase
196876
Purchase on Sigma-Aldrich

Overview

Replacement Information

Key Spec Table

CAS #Empirical Formula
256376-24-6C₂₀H₁₇FN₆

Products

Catalogue NumberPackaging Qty/Pack
196876-5MG Plastic ampoule 5 mg
Description
OverviewA cell-permeable pyrazolopyridinylpyrimidine compound that acts as a selective and potent stimulator of soluble guanylate cyclase (effective dose ~ 0.1 nM to 100 µM using recombinant soluble guanylate cyclase). The mode of activation is NO-independent and appears to be mediated through direct binding to the α1 and α2 subunits. Shown to be effective in treating numerous cardiovascular conditions in animal models. Inhibits phenylephrine-induced constriction of rabbit aortic rings (IC50 = 304 nM) and blocks collagen-induced aggregation of human platelets (IC50 = 36 nM). Does not inhibit phosphodiesterases.
Catalogue Number196876
Brand Family Calbiochem®
Synonyms5-Cyclopropyl-2-[1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-4-ylamine
References
ReferencesBoerrigter, G., et al. 2003. Circulation 107, 686.
Kalsi, J.S., et al. 2003. J Urol. 169, 761.
Koglin, M., et al. 2002. Biochem. Biophys. Res. Commun. 292, 1057.
Becker, E.M., et al. 2001. BMC Pharmacol. 1, 13.
Stasch, J.P., et al. 2001. Nature 410, 212.
Product Information
CAS number256376-24-6
ATP CompetitiveN
FormWhite solid
Hill FormulaC₂₀H₁₇FN₆
Chemical formulaC₂₀H₁₇FN₆
ReversibleN
Structure formula ImageStructure formula Image
Quality LevelMQ100
Applications
Biological Information
Primary TargetSoluble guanylate cyclase
Primary Target IC<sub>50</sub>304 nM inhibiting phenylephrine-induced constriction of rabbit aortic rings; 36 nM in blocking collagen-induced aggregation of human platelets
Purity≥98% by HPLC
Physicochemical Information
Cell permeableY
Dimensions
Materials Information
Toxicological Information
Safety Information according to GHS
Safety Information
Product Usage Statements
Storage and Shipping Information
Ship Code Ambient Temperature Only
Toxicity Standard Handling
Storage +2°C to +8°C
Protect from Light Protect from light
Do not freeze Ok to freeze
Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
Packaging Information
Transport Information
Supplemental Information
Specifications
Global Trade Item Number
Catalogue Number GTIN
196876-5MG 04055977206593

Documentation

BAY 41-2272 - CAS 256376-24-6 - Calbiochem SDS

Title

Safety Data Sheet (SDS) 

BAY 41-2272 - CAS 256376-24-6 - Calbiochem Certificates of Analysis

TitleLot Number
196876

References

Reference overview
Boerrigter, G., et al. 2003. Circulation 107, 686.
Kalsi, J.S., et al. 2003. J Urol. 169, 761.
Koglin, M., et al. 2002. Biochem. Biophys. Res. Commun. 292, 1057.
Becker, E.M., et al. 2001. BMC Pharmacol. 1, 13.
Stasch, J.P., et al. 2001. Nature 410, 212.
Data Sheet

Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

Revision05-April-2011 RFH
Synonyms5-Cyclopropyl-2-[1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-4-ylamine
DescriptionA cell-permeable pyrazolopyridinylpyrimidine compound that acts as a selective and potent stimulator of soluble guanylate cyclase (effective dose ~0.1 nM to 100 µM using recombinant soluble guanylate cyclase). The mode of activation is NO-independent and appears to be mediated through direct binding to the α1 and α2 subunits. Shown to be effective in treating numerous cardiovascular conditions in animal models. Inhibits phenylephrine-induced constriction of rabbit aortic rings (IC50 = 304 nM) and blocks collagen-induced aggregation of human platelets (IC50 = 36 nM). Does not inhibit phosphodiesterases.
FormWhite solid
CAS number256376-24-6
Chemical formulaC₂₀H₁₇FN₆
Structure formulaStructure formula
Purity≥98% by HPLC
SolubilityDMSO (10 mg/ml)
Storage Protect from light
+2°C to +8°C
Do Not Freeze Ok to freeze
Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
Toxicity Standard Handling
ReferencesBoerrigter, G., et al. 2003. Circulation 107, 686.
Kalsi, J.S., et al. 2003. J Urol. 169, 761.
Koglin, M., et al. 2002. Biochem. Biophys. Res. Commun. 292, 1057.
Becker, E.M., et al. 2001. BMC Pharmacol. 1, 13.
Stasch, J.P., et al. 2001. Nature 410, 212.